Mark Brian Anderson, PhD
Drugs ● Biologics ● Management ● Pharmaceutical
R&D ● Translational Medicine
Innovation, experience and a return on investment are the essential factors that I bring
together in the business of science incorporating clinical pathology with chemical biology producing the deliverables of
Creating value comes through innovation, teamwork,
scientific expertise, and a business savvy. I bring more than 20 years of experience in the Biopharma and Pharmaceutical R&D
My unique expertise includes clinical pathology, pharmaceutical R&D, pharmacology, and medicinal
chemistry with a team-oriented and results-oriented management style.
My experience is in infectious disease,
oncology, neurodegeneration, neurology, inflammatory disease, wound healing, antimicrobials, fungal and bacterial, cardiovascular
and pulmonary injury, and blood coagulation.
I work with industry leaders, physicians, and key opinion leaders
(KOL) in dermatology, urology, ophthalmology, oncology, sinusitis, otitis, ENT, onychomycosis, cardiovascular disease, pulmonary
injury and chronic non-healing wounds; infections, including new mechanisms of action, drug resistance, biofilm, and virulence
My experience is with new chemical and biological entities (NCE/NBE) with the goal of achieving a competitive
advantage, safe & effective marketable products and a return on investment. I have worked with many multidisciplinary
and multinational drug discovery and development teams. I develop and lead multi-disciplinary research teams utilizing effective
processes and corporate platforms to deliver high-quality new molecular entities (NME) in a fast-paced R&D environment.
The 21st century pharmaceutical landscape is rapidly changing and my experience integrates innovation, understanding
physician and patient needs, teamwork in a culturally diverse environment, and knowledge of how to drive agents and devices
to the market.
University of Massachusetts, Lowell, MA. - Clinical Pathology certification
Harvard University, Cambridge, MA. - Officer/Postdoctoral Fellow in the Department of Chemical
Biology & Chemistry completed 1992.
Purdue University, West Lafayette, IN. - Doctorate (Ph.D.) Natural Products
& Synthesis completed 1989.
University of Minnesota, Minneapolis, MN. - Bachelor of Science (B.S.) Chemistry,
Biochemistry, Microbiology Natural Products and an undergraduate Research Thesis completed 1984.
Consulting Services, Biotech Pharma Solutions - Chief Scientific Officer/Scientific Director,
2009 to Present. Consulting in drugs, biologics, medical devices, management, pharmaceutical R&D, pharmacology, formulations,
toxicology, international projects, posology, and translational medicine. Areas of expertise include infectious disease, inflammatory
disease, oncology, neurology, antimicrobials both bacterial and fungal.
Consultant at MED360 / MNOW™ Experts
- February 2012 to present. MNOW™ Experts is A LeadPhysician Resource; MED360 is A Division of WorldOne.
at NovaBay Pharmaceuticals, Inc. January 2012 to present. Infectious disease and biofilm both bacterial and fungal in
ophthalmology, dermatology, urology and wound healing.
NovaBay Pharmaceuticals, Inc.:
Chief Scientific Officer, October 2009 to January 2012 – Pharmaceutical CSO in infectious disease including
ophthalmology/ENT, dermatology, urology, sinusitis, onychomycosis, and hospital chronic non-healing wounds (wound healing),
biofilm, drug resistance, and virulence factors. Collaboration contacts Alcon (US) and Galderma (US & Fr).
Services, Biotech Pharma Solutions - President and Chief Scientific Officer/Scientific Director, 2009. Consulting in drugs,
biologics, medical devices, management, pharmaceutical R&D, pharmacology, formulations, toxicology, international projects,
posology, and translational & functional medicine.
Myriad Genetics & Myriad Pharmaceuticals:
Vice President; Chemistry R&D, 2003 to 2009 – Oncology (Cancer), Alzheimer’s Genetics, HIV, infectious disease,
inflammatory disease, blood coagulation, disease pathology, blood-brain barrier penetration, formulations, salt forms, polymorphs,
selection of IND candidates, clinical development team, posology, epigenetic and novel targets.
Pharmaceuticals: Senior Director, 2002 to 2003 – Concentration in Infectious disease (bacterial and
fungal), US & International collaborations and management.
Pfizer La Jolla Labs –
Agouron Pharmaceuticals: Associate Director of Medicinal Chemistry, 1997 to 2002 – Neuroendocrine, Cancer
(oncology), viral disease, infectious disease, medicinal chemistry, project leadership, drug design, SBDD, combinatorial lead
expansion, and management.
Ligand Pharmaceuticals - Glycomed, Inc: Senior
Research Scientist 1992 to 1997 - International project leadership, oncology, inflammatory disease and cell-adhesion, wound
healing, mediated pathologies, pulmonary and cardiovascular injury, asthma, and drug formulations.
AND PROFESSIONAL SOCIETIES
2012 Presentations: R. Bryan Miller Symposium, March 15-16 at UC Davis.
Invited speaker on “Hydrogel Drug Delivery for the infectious disease; The Treatment of Impetigo”.
2011 Presentations: NeutroPhase® Product Launch at the Symposium on Advanced Wound Care (SAWC), Las
Vegas, NV; October 13 – 15, 2011; Wound Healing, Infectious disease invited talk on Impetigo at the Cambridge Healthtech
Institute (CHI) Conference; San Diego, CA 2011; Infectious disease invited talk on Impetigo at the 3rd Anti-Infectives Summit
(IQPC/AIS); The Westin Philadelphia, PA; January 24 – 26, 2011; Invited panel discussion on Corporate Collaborations
& Partners at the 3rd Anti-Infectives Summit (IQPC/AIS); The Westin Philadelphia, PA; January 24 – 26, 2011.
Professionals Society (RAC); Association for Molecular Pathology (AMP); American Society for Investigative Pathology (ASIP);
American Society of Microbiology (ASM); American Chemical Society (ACS).
Wound Care: Society for Advanced Wound
Care (SAWC), Wound Healing Society (WHS).
Medical Devices: Multidisciplinary Alliance Against Device-Related Infections
(MADRI), Pre-Filled Syringes (4th PFS London).
Ophthalmology: Association for Research in Vision and Ophthalmology
(ARVO), American Academy of Ophthalmology (AAO).
Dermatology, Urology & Other: Interscience Conference on Antimicrobial
Agents & Chemotherapy (ICAAC), and Infectious Diseases Society of America (IDSA).
SELECTED CONTINUING EDUCATION COLLOQUIUMS
ARVO Clinical Trials Education Series: “Designing and Managing Clinical Trials
in Eye Research.” May 1, 2010, 8:30 am – 5pm, Fort Lauderdale, FL.
UCSD School of Medicine, Office
of Continuing Medical Education ACS/UCSD Colloquium: “Angiogenesis Inhibitors in the Treatment of Solid Tumors”;
Lee Rosen, M.D. January 22, 2001.
UCSD School of Medicine, Office of Continuing Medical Education ACS/UCSD Colloquium:
“Nonmyeloablative Stem Cell Transplantation Using Low-dose Total Body Irradiation, Cyclosporine and MMF”; Peter
McSweeney, M.D. February 26, 2001.
UCSD School of Medicine, Office of Continuing Medical Education ACS/UCSD Colloquium:
“Current Therapeutic Opinions in the Management of Cell Malignancies”; Michael Keating. November 6, 2000.
UCSD School of Medicine, Office of Continuing Medical Education ACS/UCSD Colloquium: “New Endocrine Approaches for
Breast Cancer: Oncology Prevention and Treatment”; C. Kent Osborne, M.D. October 23, 2000.
UCSD School of
Medicine, Office of Continuing Medical Education ACS/UCSD Colloquium: “New Approaches to Therapy of Acute Myelogenous
Leukemia, blood coagulation”; Richard Stone, M.D. October 2, 2000.
UCSD School of Medicine, Office of Continuing
Medical Education ACS/UCSD Colloquium: “Biology and Therapy of Advanced Prostate Cancer, Oncology”; Christopher
Logothetis, M.D. June 8, 1999.
OVERVIEW OF INTELLECTUAL
100+ US & international issued and
pending patent applications covering cancer (e.g. glioblastoma, methods for treating cancer, blood-brain barrier crossing
agents, etc.); infectious disease (e.g. HIV maturation inhibitors, novel anti HIV agents, etc.); cancer agents associated
with signal transduction (e.g. caspase activators and inducers of apoptosis); neuroendocrine (e.g. non-peptide GnRH agents);
neurodegeneration (e.g. Alzheimer’s disease, neurology, oncology); kinases (e.g. cell cycle); viral infections; vascular
disrupting agents; inflammatory diesease, autoimmune diseases; etc. The end result is a history of multiple agents in the
clinic. See below.
OVERVIEW OF PUBLICATIONS
50+ publications and cited publications in infectious disease
clinical studies (e.g. impetigo, viral conjunctivitis); cancer (e.g. vascular disrupting agents, novel agents, oncology);
neurodegeneration (Alzhiemer’s, neurology); inflammatory disease (e.g. lung and cardiac injuries); elucidation novel
mechanisms of action; bacterial biofilm; virulence factors, drug resistance; reviews (e.g. 2009 - Current Bioactive
Compounds, 2003 - Annual Reports in Medicinal Chemistry, 1994 - Burger's Medicinal Chemistry Chapter 22), etc.
40+ presentations and posters at Cambridge Healthtech Institute
(CHI), Anti-Infectives Summit, Society of Toxicology and American Heart Association; and posters at e.g. ARVO, ICAAC, IDSA,
Key Words: pathology, chemistry, medicinal chemistry, biology, chemical biology,
business acumen, Harvard, Purdue, University of Minnesota, drug design, small molecule, drug discovery, chemical proteomics,
Director, Senior Director, Vice President, cancer, oncology, HIV, ALZHEIMERS DISEASE, ALZHEIMERS, neurology, BLOOD BRAIN
BARRIER, VASCULAR DISRUPTING AGENTS, VASCULAR TARGETING AGENTS, virulence factors, prodrugs, kinase, CASPASE, drug design,
admet, infectious disease, apoptosis, patents, endocrine, antiviral, GNRH, Selectin, formulations, inflammatory disease, cell
adhesion, glycomimetic, mark anderson, mark brain anderson, chief scientific officer, CSO, non-healing wounds, wound healing.